Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Crucell

- PMLiVE

CRUK forges £30m ‘post-Brexit’ R&D alliance

Joins forces with organisations in Italy and Spain

- PMLiVE

MHRA cut out of regulatory work as Brexit looms

This year the regulatory body was only awarded two contracts to serve as the lead assessor on NDAs

- PMLiVE

Brexit medicine stockpiling could cost £2bn

Cost will be incurred whether a 'no deal' Brexit is avoided or not

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

- PMLiVE

Confidence in UK’s post-Brexit healthcare sector on the wane

Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure

- PMLiVE

Can a post-Brexit UK stay aligned with Europe on clinical research?

There's still no guarantee the UK can keep in step with EU

- PMLiVE

Pharma survey: No Brexit is the best option

But many believe a 'no deal' Brexit most likely outcome

- PMLiVE

As ‘No Deal’ fears grow, pharma can’t rely on transition period

UK could still remain part of EMA 'club' until 2020 - but time is running out

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Sanofi latest to reveal Brexit stockpiling of drugs

Company says UK job losses inevitable in event of hard or no deal Brexit

- PMLiVE

Minister reveals medicines stockpiling plan for No Deal Brexit

Hancock says plans being made - but will come at a cost

- PMLiVE

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

The latest from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links